Drug Development
Retraction: Tumors with TSC mutations are sensitive to CDK7 inhibition through NRF2 and glutathione depletion.
The Journal of experimental medicine 2026-Jul-06
Zarei Mahsa, Du Heng, Nassar Amin H, Yan Rachel E, Giannikou Krinio, Johnson Sneha H, Lam Hilaire C, Henske Elizabeth P, Wang Yubao, Zhang Tinghu, Asara John, Kwiatkowski David J
Abstract
Key Findings
- Tumors with TSC mutations show sensitivity to CDK7 inhibition.
- This sensitivity is mediated through NRF2 and glutathione depletion.
- Targeting CDK7 may offer a therapeutic approach for tumors harboring TSC mutations.
Clinical Significance
The study suggests that CDK7 inhibitors could be developed as targeted therapies for patients with tumors containing TSC mutations by exploiting vulnerabilities related to NRF2 and glutathione pathways.
Citation
Zarei Mahsa, Du Heng, Nassar Amin Het al.. Retraction: Tumors with TSC mutations are sensitive to CDK7 inhibition through NRF2 and glutathione depletion. The Journal of experimental medicine. 2026-Jul-06.
DOI: 10.1084/jem.2019025105292026r